Asper’s genetics lab ISO15189 accreditation scope extension

Published 19/08/2022

Estonian Accreditation Centre confirmed Asper Biogene’s Medical laboratory ISO15189 accreditation scope extension as of 20.07.2022. Celiac disease genetic risk assessment is also conforms to the requirements of ISO15189:2012.

Expo 2020 Dubai

Published 28/01/2022

Come join us for a business seminar “Digital nation. Personalized solutions for healthcare & wellbeing” at Expo 2020 Dubai!

Together with a distinguished Estonian health-tech delegation we will introduce how high-level research has given rise to globally successful life-science companies. Our seminar will cover topics like:
🔷 Vision speech explaining the success story of Estonian Health Tech
🔷 Real-life innovations for personalized cancer prevention
🔷 How digital health solutions bring care back to healthcare
🔷 Changes and challenges in the molecular diagnostics

The seminar takes place on January 31 in the @EXPO 2020 Estonian Pavilion.

👉 Read more and register here: https://business.tartu.ee/expo/health/

A perfect opportunity to network with the world’s most advanced digital society and companies representing it: Antegenes, Asper Biogene, Competence Centre on Health Technologies, DocuMental, The Institute of Genomics University of Tartu, Migrevention, Nordwise, Triumf Health, Solis Biodyne, Enterprise Estonia, Estonian Connected Health Cluster, Tartu Biotechnology Park, Smart City Tartu.

 

Cooperation with GJ Klinika

Published 28/10/2021

We are excited to announce that we have started cooperation with GJ Klinika from Lithuania. GJ Klinika provides a wide range of genetic testing services including reproductive genetics, prenatal diagnostics, newborn genetic testing, and also cardio- and pharmacogenetics. Visit https://gjklinika.lt to learn more.

Asper Oncogenetics news

Published 22/09/2021

New panel specifically targeting mutations in 25 genes implicated in renal cancer is now available. In addition, we have added genes to the melanoma and the prostate cancer gene sets. Visit asper-oncogenetics to learn more!

Antidepressants PGx test

Published 31/03/2021

We are pleased to announce that Asper Biogene has launched a new pharmacogenetic test – Antidepressants PGx – for assessing metabolic response to antidepressant medications.

Antidepressants PGx test includes carefully selected and strictly evidence-based genetic markers. The test provides dosing recommendations for selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) based on guidelines published by Clinical Pharmacogenetics Implementation Consortium (CPIC). Read more at www.asperbio.com/asper-pharmacogenetics/antidepressants-pgx/

CNV analysis

Published 12/02/2021

All NGS panels in our testing menu now include CNV analysis. Panels for frontotemporal dementia, tuberous sclerosis, microcephaly, and hereditary spastic paraplegia cover the analysis of clinically relevant non-coding variants. Learn more at  www.asperbio.com/asper-neurogenetics

2021 Annual Ataxia Conference

Published 09/02/2021

Asper Biogene is attending the Annual Ataxia Conference, 10-13 March, organised by the National Ataxia Foundation. The conference will be held online and brings together leading ataxia experts. Do not miss the opportunity to get informed about recent research on ataxias and developments in treatment targets and diagnostics.
Take a close look at our virtual booth and learn about Asper Biogene’s genetic testing options for different types of ataxias. Come as you are: Ataxia unmasked!

Download a leaflet of ataxia testing options

Download a table of tested genes and diseases

Updated Asper Dysmorphology menu

Published 08/12/2020

We have launched an updated Asper Dysmorphology menu. New phenotypically relevant disease-causing genes have been added to many of the panels including brain malformation, microcephaly, skeletal dysplasia, craniosynostosis and several other panels. Visit www.asperbio.com/asper-dysmorphology to see the whole list of tests.

Updates in Asper Neurogenetics testing menu

Published 21/10/2020

We now offer a new test for Congenital Muscular Dystrophy, which covers 29 genes and disease-associated non-coding variants. Cornelia de Lange Syndrome and Limb-Girdle Muscular Dystrophy panels also include the analysis of non-coding variants. In addition, we have added genes to the Limb-Girdle Muscular Dystrophy gene set. Learn more at www.asperbio.com/asper-neurogenetics/

Hereditary ataxia

Published 20/10/2020

We have expanded our testing options for different types of hereditary ataxia. NGS panel now covers 148 genes and selected non-coding variants associated with spinocerebellar ataxia, episodic ataxia, and cerebellar ataxia. Repeat expansion analysis is available for 14 genes. CNVs are detected based on sequencing data or by Chromosomal Microarray Analysis. Mitochondrial genome sequencing can also be performed to determine the specific genetic cause of hereditary ataxia. Read more at https://www.asperbio.com/asper-neurogenetics/hereditary-ataxia/

 

EU60187 Project

Published 22/07/2020

Asper Biogene is working on the new project – „Prototype development of pharmacogenetic test“.

Project goals: 

1. To develop a prototype of pharmacogenetic test to maximize drug efficacy and reduce adverse drug reactions for most common drugs (at least 30 drugs) listed in the internationally agreed pharmacogenetic clinical practice guidelines.

2. To develop medical informatics tools for the automatic generation and sharing of web-based pharmacogenetic test reports with doctors and patients through Health and Welfare Information Systems Centre (HWISC) database.

Project period: 06.07.2020 – 06.01.2021

Project has been supported by Enterprise Estonia (EAS) from The European Regional Development Fund. Financial support is up to 24 500,00 Euros.

Asper Reprogenetics News

Published 18/05/2020

Female infertility and male factor infertility panels have undergone an extensive upgrade. The panels now consist of 128 and 138 genes respectively. Female infertility panel also contains testing of CGG trinucleotide repeat in the FMR1 gene. Please see www.asperbio.com/asper-reprogenetics/ for more information.

Updated NGS panels

Published 28/04/2020

Several NGS panels have been updated, including panels for Brain Malformations, Spinocerebellar Ataxias, and Sensorineural Hearing Loss. Find more about updates at www.asperbio.com/NGS-panels

Important announcement

Published 18/03/2020

In critical situation, due to COVID-19 faced by many countries we would like to ensure that we continue providing you with genetic testing services. Our key goal is to continuously offer diagnostic solutions that support healthcare professionals with valuable information and thus contribute to improving patient care. We are committed to maintain the highest level of quality standards in all operations.

In our everyday practice, we follow the WHO guidelines and protective measures of national health authorities to establish safety and health of our employees and customers.

Our laboratory team, clinical and scientific teams are operational and available as usual. As well as customer service will continue to offer assistance. If any new information under these changing circumstances become available we will notify you as soon as possible.

Be safe and healthy! If we can be any of assistance, please do not hesitate to contact us.